Antimicrobial resistance in the Netherlands is remaining reasonably stable Antimicrobial resistance is increasing on a global level. It is difficult to treat infections caused by resistant bacteria.
If you have found a tick bite, check for others! One in five people who report having been bitten by a tick on Tekenrader.nl report that they have more than one tick bite. If you have found one tick bite, check for others!
Updated immunisation recommendation for measles: early vaccination before travel A number of European countries are currently seeing outbreaks of measles. Before the start of the summer season, RIVM has therefore updated its immunisation recommendation for measles.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Protection of Defence personnel against health risks of chromium-6 was inadequate From 1984-2006, employees of the Dutch Ministry of Defence were exposed to chromium-6 during maintenance work.
Lyme disease cases have quadrupled According to a survey by RIVM , 27,000 people were infected with Lyme disease in 2017. In 2014, the last time RIVM reported on the incidence of tick-borne disease, this number was 25,000.
Chance of ESBL contamination via livestock farming is small ESBL is an enzyme, produced by certain bacteria, which makes these bacteria resistant to antibiotics.
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Risk of measles outbreaks increases with decreasing vaccination coverage Vaccination coverage for vaccinations in the Dutch National Vaccination Program (NIP) decreased slightly by about half a percent for the third consecutive year.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.